Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report

The COVID‐19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10–13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium “Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases” to discuss the successes and challenges of the COVID‐19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID‐19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID‐19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements—notably, in low‐to‐middle income countries—must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.

[1]  E. Saphire,et al.  Neutralizing Antibodies against Lassa Virus Lineage I , 2022, mBio.

[2]  D. Feikin,et al.  Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera , 2022, Vaccines.

[3]  E. Saphire,et al.  Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies , 2022, Cell reports.

[4]  G. Guyatt,et al.  Effect of Early Treatment with Ivermectin among Patients with Covid-19 , 2022, The New England journal of medicine.

[5]  S. Panda,et al.  Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against alpha, Beta, Delta and omicron variants of concern. , 2022, Journal of travel medicine.

[6]  N. Lurie,et al.  Delivering Pandemic Vaccines in 100 Days - What Will It Take? , 2022, The New England journal of medicine.

[7]  M. Nilges,et al.  Bat coronaviruses related to SARS-CoV-2 and infectious for human cells , 2022, Nature.

[8]  Robert J. Fischer,et al.  Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model , 2022, Research square.

[9]  A. Nardone,et al.  SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 , 2022, BMJ Global Health.

[10]  N. Foskett,et al.  Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination , 2021, The Lancet Global Health.

[11]  Lydia M. Roberts,et al.  Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques , 2021, Life Science Alliance.

[12]  OUP accepted manuscript , 2022, Journal of Travel Medicine.

[13]  Hamed Khakzad,et al.  Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2 , 2022, Frontiers in Immunology.

[14]  W. Lipkin,et al.  Natural history of nonhuman primates after conjunctival exposure to Ebola virus , 2021, bioRxiv.

[15]  A. Nardone,et al.  Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021 , 2021, medRxiv.

[16]  J. Lopez Bernal,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.

[17]  A. Nardone,et al.  Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID‐19 pandemic , 2021, Influenza and other respiratory viruses.

[18]  Hyeong Mi Kim,et al.  Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study , 2021, Science.

[19]  Jitendra Narayan,et al.  Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India , 2021, Viruses.

[20]  G. Guyatt,et al.  Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial , 2021, The Lancet Global Health.

[21]  M. Chen,et al.  Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors , 2021, The New England journal of medicine.

[22]  H. Mullerova,et al.  Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis , 2021, The Lancet.

[23]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[24]  R. Horstmeyer,et al.  Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR , 2021, Science Translational Medicine.

[25]  G. Screaton,et al.  Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine , 2021, ACS central science.

[26]  Robert J. Fischer,et al.  ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge , 2021, NPJ vaccines.

[27]  J. Woodcock,et al.  Trends in COVID-19 therapeutic clinical trials , 2021, Nature Reviews Drug Discovery.

[28]  Nguyen H. Tran,et al.  Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.

[29]  Timothy D. Flietstra,et al.  High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay , 2020, Scientific Reports.

[30]  A. Casadevall,et al.  Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. , 2020, The New England journal of medicine.

[31]  R. Hai,et al.  H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model , 2020, mBio.

[32]  J. Epstein,et al.  Nipah virus dynamics in bats and implications for spillover to humans , 2020, Proceedings of the National Academy of Sciences.

[33]  D. Skovronsky,et al.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[34]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[35]  J. Epstein,et al.  Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats , 2020, PLoS pathogens.

[36]  A. Fauci,et al.  Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.

[37]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[38]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[39]  M. Chen,et al.  A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.

[40]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[41]  G. Alter,et al.  Dissecting antibody-mediated protection against SARS-CoV-2 , 2020, Nature Reviews Immunology.

[42]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[43]  Joshua C. Johnson,et al.  Natural History of Aerosol Induced Lassa Fever in Non-Human Primates , 2020, Viruses.

[44]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[45]  Anna María Nápoles,et al.  COVID-19 and Racial/Ethnic Disparities. , 2020, JAMA.

[46]  E. Fischer,et al.  Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 , 2020, Nature.

[47]  B. Graham,et al.  Prototype pathogen approach for pandemic preparedness: world on fire. , 2020, The Journal of clinical investigation.

[48]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[49]  F. I. Ibukun,et al.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development , 2020, Viruses.

[50]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[51]  Eurosurveillance Editorial Team Note from the editors: novel coronavirus (2019-nCoV) , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[52]  C. Muñoz-Fontela,et al.  Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice , 2019, JCI insight.

[53]  H. Feldmann,et al.  Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death , 2019, The Journal of clinical investigation.

[54]  J. Armengaud,et al.  Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot , 2019, Science Translational Medicine.

[55]  James E. Robinson,et al.  Antibody therapy for Lassa fever. , 2019, Current opinion in virology.

[56]  E. Saphire,et al.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization , 2019, Cell.

[57]  H. Feldmann,et al.  Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge , 2019, Science Translational Medicine.

[58]  P. Daszak,et al.  Transmission of Nipah Virus — 14 Years of Investigations in Bangladesh , 2019, The New England journal of medicine.

[59]  P. Daszak,et al.  Using healthcare-seeking behaviour to estimate the number of Nipah outbreaks missed by hospital-based surveillance in Bangladesh. , 2019, International journal of epidemiology.

[60]  S. Günther,et al.  T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. , 2018, The Journal of infectious diseases.

[61]  Tchoyoson C. C. Lim,et al.  Nipah Virus Infection , 2018, Journal of Clinical Microbiology.

[62]  C. Picard,et al.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins , 2018, Journal of Virology.

[63]  Catharine I Paules,et al.  The Critical Role of Biomedical Research in Pandemic Preparedness. , 2017, JAMA.

[64]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[65]  J. Epstein,et al.  Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh , 2017, Emerging infectious diseases.

[66]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[67]  L. Madoff,et al.  ProMED-mail: 22 years of digital surveillance of emerging infectious diseases. , 2017, International health.

[68]  G. Quérat,et al.  Implementation of a non‐human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations , 2017, Antiviral research.

[69]  S. Günther,et al.  Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination , 2017, Scientific Reports.

[70]  James O. Lloyd-Smith,et al.  Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting , 2016, Science.

[71]  Lauren A. Cowley,et al.  Unique human immune signature of Ebola virus disease in Guinea , 2016, Nature.

[72]  Barney S. Graham,et al.  Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.

[73]  V. Nene,et al.  Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever , 2016, Scientific Reports.

[74]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[75]  Jay B. Varkey,et al.  Human Ebola virus infection results in substantial immune activation , 2015, Proceedings of the National Academy of Sciences.

[76]  H. Feldmann,et al.  Foodborne Transmission of Nipah Virus in Syrian Hamsters , 2014, PLoS pathogens.

[77]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[78]  H. Feldmann,et al.  Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route , 2012, Scientific Reports.

[79]  H. Feldmann,et al.  Nipah Virus Transmission in a Hamster Model , 2011, PLoS neglected tropical diseases.

[80]  L. Madoff ProMED-mail: an early warning system for emerging diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  Paul Milligan,et al.  Bulletin of the World Health Organization , 2017 .

[82]  J. Lederberg,et al.  COMMITTEE ON EMERGING MICROBIAL THREATS TO HEALTH , 1992 .

[83]  E. Stephenson,et al.  Effect of environmental factors on aerosol‐induced lassa virus infection , 1984, Journal of medical virology.

[84]  Ebola haemorrhagic fever in Zaire, 1976. , 1978, Bulletin of the World Health Organization.